Emmanuel Stephen-Victor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Emmanuel Stephen-Victor has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Elena Crestani
Division of Immunology, Boston Children’s Hospital, Boston, MA, USA
4 shared publications - Jason Fong
Division of Immunology Boston Children's Hospital Boston Massachusetts USA
4 shared publications - Mehdi Benamar
Division of Immunology, Boston Children’s Hospital, Harvard Medical School, Boston, USA
4 shared publications - Jagadeesh Bayry
Department of Biological Sciences & Engineering, Indian Institute of Technology Palakkad, Palakkad, India
3 shared publications - Louis-Marie Charbonnier
Division of Immunology, Boston Children’s Hospital, Boston, Massachusetts, USA
3 shared publications - Talal A. Chatila
Division of Immunology, Boston Children’s Hospital, Boston, MA, USA
3 shared publications
Latest Publications
- 5 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (861)
Fecal microbiome transplant in food allergy in humans and mice identifies a role for bile acid metabolites in oral tolerance
The gut microbiome has been implicated in the pathogenesis of food allergy (FA), prompting microbiome-focused interventions. We evaluated, in a phase 1 open-label trial (NCT02960074), the safety and efficacy of oral encapsulated fecal microbiome transplantation (FMT) in 15 adults with peanut allergies. An increase in the peanut reactivity threshold was noted in 3 of 10 participants not pretreated with antibiotics and 3 of 5 participants pretreated with antibiotics, without safety issues. In responders, FMT increased tolerogenic RORγt + regulatory T cells (T reg cells) and decreased T helper 2 cells (T H 2 cells). Mice transplanted with the microbiomes of post-FMT responders were protected from FA in association with increased RORγt + T reg cell percentages and increased colonization with members of the gut Bacteroides . In both humans and mice, protection by FMT was associated with increased bile acid metabolites. Deletion of a bile salt hydrolase in a candidate protective Bacteroides abrogated FA suppression in mice. These results suggest that FMT is a safe and potentially promising therapeutic modality for treating FA.
- 5 August 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 18 (861)
Fecal microbiome transplant in food allergy in humans and mice identifies a role for bile acid metabolites in oral tolerance
The gut microbiome has been implicated in the pathogenesis of food allergy (FA), prompting microbiome-focused interventions. We evaluated, in a phase 1 open-label trial (NCT02960074), the safety and efficacy of oral encapsulated fecal microbiome transplantation (FMT) in 15 adults with peanut allergies. An increase in the peanut reactivity threshold was noted in 3 of 10 participants not pretreated with antibiotics and 3 of 5 participants pretreated with antibiotics, without safety issues. In responders, FMT increased tolerogenic RORγt + regulatory T cells (T reg cells) and decreased T helper 2 cells (T H 2 cells). Mice transplanted with the microbiomes of post-FMT responders were protected from FA in association with increased RORγt + T reg cell percentages and increased colonization with members of the gut Bacteroides . In both humans and mice, protection by FMT was associated with increased bile acid metabolites. Deletion of a bile salt hydrolase in a candidate protective Bacteroides abrogated FA suppression in mice. These results suggest that FMT is a safe and potentially promising therapeutic modality for treating FA.
- 22 January 2025
- Published by Springer Nature in Nature
- Vol. 638 (8051) , 760-768
RELMβ sets the threshold for microbiome-dependent oral tolerance
Tolerance to dietary antigens is critical for avoiding deleterious type 2 immune responses resulting in food allergy (FA) and anaphylaxis1,2. However, the mechanisms resulting in both the maintenance and failure of tolerance to food antigens are poorly understood. Here we demonstrate that the goblet-cell-derived resistin-like molecule β (RELMβ)3,4 is a critical regulator of oral tolerance. RELMβ is abundant in the sera of both patients with FA and mouse models of FA. Deletion of RELMβ protects mice from FA and the development of food-antigen-specific IgE and anaphylaxis. RELMβ disrupts food tolerance through the modulation of the gut microbiome and depletion of indole-metabolite-producing Lactobacilli and Alistipes. Tolerance is maintained by the local production of indole derivatives driving FA protective RORγt+ regulatory T (Treg) cells5 through activation of the aryl hydrocarbon receptor. RELMβ antagonism in the peri-weaning period restores oral tolerance and protects genetically prone offspring from developing FA later in life. Together, we show that RELMβ mediates a gut immune–epithelial circuit regulating tolerance to food antigens—a novel mode of innate control of adaptive immunity through microbiome editing—and identify targetable candidates in this circuit for prevention and treatment of FA.
- 22 January 2025
- Published by Springer Nature in Nature
- Vol. 638 (8051) , 760-768
RELMβ sets the threshold for microbiome-dependent oral tolerance
Tolerance to dietary antigens is critical for avoiding deleterious type 2 immune responses resulting in food allergy (FA) and anaphylaxis1,2. However, the mechanisms resulting in both the maintenance and failure of tolerance to food antigens are poorly understood. Here we demonstrate that the goblet-cell-derived resistin-like molecule β (RELMβ)3,4 is a critical regulator of oral tolerance. RELMβ is abundant in the sera of both patients with FA and mouse models of FA. Deletion of RELMβ protects mice from FA and the development of food-antigen-specific IgE and anaphylaxis. RELMβ disrupts food tolerance through the modulation of the gut microbiome and depletion of indole-metabolite-producing Lactobacilli and Alistipes. Tolerance is maintained by the local production of indole derivatives driving FA protective RORγt+ regulatory T (Treg) cells5 through activation of the aryl hydrocarbon receptor. RELMβ antagonism in the peri-weaning period restores oral tolerance and protects genetically prone offspring from developing FA later in life. Together, we show that RELMβ mediates a gut immune–epithelial circuit regulating tolerance to food antigens—a novel mode of innate control of adaptive immunity through microbiome editing—and identify targetable candidates in this circuit for prevention and treatment of FA.
- Open Access
- 30 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (75) , eabl8357
A Stk4-Foxp3–NF-κB p65 transcriptional complex promotes T reg cell activation and homeostasis
The molecular programs involved in regulatory T (T reg ) cell activation and homeostasis remain incompletely understood. Here, we show that T cell receptor (TCR) signaling in T reg cells induces the nuclear translocation of serine/threonine kinase 4 (Stk4), leading to the formation of an Stk4–NF-κB p65–Foxp3 complex that regulates Foxp3- and p65-dependent transcriptional programs. This complex was stabilized by Stk4-dependent phosphorylation of Foxp3 on serine-418. Stk4 deficiency in T reg cells, either alone or in combination with its homolog Stk3, precipitated a fatal autoimmune lymphoproliferative disease in mice characterized by decreased T reg cell p65 expression and nuclear translocation, impaired NF-κB p65–Foxp3 complex formation, and defective T reg cell activation. In an adoptive immunotherapy model, overexpression of p65 or the phosphomimetic Foxp3 S418E in Stk3/4-deficient T reg cells ameliorated their immune regulatory defects. Our studies identify Stk4 as an essential TCR-responsive regulator of p65-Foxp3–dependent transcription that promotes T reg cell–mediated immune tolerance.
- 30 September 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 7 (75) , eabl8357
Open AccessA Stk4-Foxp3–NF-κB p65 transcriptional complex promotes T reg cell activation and homeostasis
The molecular programs involved in regulatory T (T reg ) cell activation and homeostasis remain incompletely understood. Here, we show that T cell receptor (TCR) signaling in T reg cells induces the nuclear translocation of serine/threonine kinase 4 (Stk4), leading to the formation of an Stk4–NF-κB p65–Foxp3 complex that regulates Foxp3- and p65-dependent transcriptional programs. This complex was stabilized by Stk4-dependent phosphorylation of Foxp3 on serine-418. Stk4 deficiency in T reg cells, either alone or in combination with its homolog Stk3, precipitated a fatal autoimmune lymphoproliferative disease in mice characterized by decreased T reg cell p65 expression and nuclear translocation, impaired NF-κB p65–Foxp3 complex formation, and defective T reg cell activation. In an adoptive immunotherapy model, overexpression of p65 or the phosphomimetic Foxp3 S418E in Stk3/4-deficient T reg cells ameliorated their immune regulatory defects. Our studies identify Stk4 as an essential TCR-responsive regulator of p65-Foxp3–dependent transcription that promotes T reg cell–mediated immune tolerance.
- Top Cited Papers
Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity
- Open Access
- 2 July 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (3) , 2002182
Potential of regulatory T-cell-based therapies in the management of severe COVID-19
In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T-cell-based therapies could be considered for patient managementhttps://bit.ly/3eKqWPo
- 2 July 2020
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 56 (3) , 2002182
Open AccessPotential of regulatory T-cell-based therapies in the management of severe COVID-19
In view of dysregulated immune response, “cytokine storm” and inflammation-induced lung damage in severely ill COVID-19 patients, we propose that CD4+CD25+FoxP3+ regulatory T-cell-based therapies could be considered for patient managementhttps://bit.ly/3eKqWPo
- 14 May 2018
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 14 (7) , 390-392
Multimerized IgG1 Fc molecule as an anti-inflammatory agent
- 14 May 2018
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 14 (7) , 390-392
Multimerized IgG1 Fc molecule as an anti-inflammatory agent
- 4 May 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (23)
Regulatory T cells induce activation rather than suppression of human basophils
Human basophils are refractory to suppression by T regs and undergo activation by an IL-3– and STAT5-dependent mechanism.
- 4 May 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 3 (23)
Regulatory T cells induce activation rather than suppression of human basophils
Human basophils are refractory to suppression by T regs and undergo activation by an IL-3– and STAT5-dependent mechanism.